Biotechnology & Life Sciences India On demand · 24-48h

India Genomics, Proteomics, and Target-Based Drug Discovery Outsourcing Market Strategic Research Report

India Genomics, Proteomics, and Target-Based Drug Discovery …
$1,495 USD
Market Research Reports
Strategic Research Report
India Genomics, Proteomics, and Target-Based Drug Discovery Outsourcing Market
$1.18B2025
12.6%CAGR
2032Forecast
Market Research Reports · India
Market Research Reports Intelligence Series

By Type: Genomics Services, Proteomics Services, Target ID & Validation

By Application: Hit-to-Lead Optimization, Bioinformatics Services, Oncology Applications

Regional Forecast: South India — Karnataka, Telangana & Tamil Nadu (Bengaluru-Hyderabad-Chennai Cluster), West India — Maharashtra (Pune-Mumbai Pharma & Biotech Hub), North India — Delhi NCR, Chandigarh & Uttar Pradesh (NOIDA Biotech Corridor), East India — West Bengal & Odisha (Emerging CRO & Academic Cluster), Central India — Madhya Pradesh & Chhattisgarh (Government-Backed Research Parks)

Key Players: Syngene International, Jubilant Biosys, Aurigene Oncology (Dr. Reddy's Subsidiary), Lambda Therapeutic Research, Anthem Biosciences, Divi's Laboratories (Discovery Services Division), Aragen Life Sciences (formerly GVK Biosciences), Connexios Life Sciences, Eurofins Scientific India (Genomics Division), Xcelris Labs

Region: India
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Market size 2025
$1.18B
Billion USD
Forecast CAGR
12.6%
2025-2032
Forecast 2032
$2.7B
Projected
Regions
5
South India — Karnataka, Telangana & Tamil Nadu (Bengaluru-Hyderabad-Chennai Cluster) · West India — Maharashtra (Pune-Mumbai Pharma & Biotech Hub) · North India — Delhi NCR, Chandigarh & Uttar Pradesh (NOIDA Biotech Corridor) · East India — West Bengal & Odisha (Emerging CRO & Academic Cluster) · Central India — Madhya Pradesh & Chhattisgarh (Government-Backed Research Parks)

نظرة عامة

The India genomics, proteomics, and target-based drug discovery outsourcing market represents one of the fastest-expanding segments within the country's broader contract research and life sciences services economy. Valued at approximately USD 1.18 billion in 2024, the market encompasses a diverse portfolio of services spanning next-generation sequencing, mass spectrometry-based proteomic profiling, bioinformatics pipeline development, target identification and validation, hit-to-lead optimization, and ADMET screening — all delivered by Indian contract research organizations to domestic and international pharmaceutical, biotechnology, and academic clients. India's combination of scientific talent density, cost-indexed research productivity, and a rapidly maturing regulatory framework has positioned it as a preferred destination for early-phase drug discovery outsourcing, particularly from North American and European innovator companies seeking to extend research capital while maintaining scientific rigor.

Market snapshot

India Genomics, Proteomics, and Target-Based Drug Discovery Outsourcing Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 12.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.18B
2025
Forecast
$2.7B
2032
CAGR
12.6%
2025–2032
Regions
5
global
Key companies
Syngene InternationalJubilant BiosysAurigene Oncology (Dr. Reddy's Subsidiary)Lambda Therapeutic ResearchAnthem BiosciencesDivi's Laboratories (Discovery Services Division)Aragen Life Sciences (formerly GVK Biosciences)Connexios Life Sciences
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Genomics ServicesProteomics ServicesTarget ID & Validation
By Application
Hit-to-Lead OptimizationBioinformatics ServicesOncology Applications

Table of contents

Click a chapter to expand
01Executive Summary
  • 1.1 Market Synopsis
  • 1.2 Key Findings
  • 1.3 Strategic Recommendations
02Industry Overview & Forecast
  • 2.1 Market Definition & Scope
  • 2.2 Market Value Forecast, 2025-2032 (Value)
  • 2.3 CAGR Analysis & Confidence Intervals
  • 2.4 Historical Market Review, 2019-2024
  • 2.5 Scenario Analysis (Base, Bull, Bear Cases)
03Market Segmentation by Service Type
  • 3.1 Market by Service Type Overview
  • 3.2 Genomics Services — Whole Genome Sequencing, NGS, Genotyping (Value)
  • 3.3 Proteomics Services — Mass Spectrometry, Protein Profiling, Biomarker Discovery (Value)
  • 3.4 Target Identification & Validation Services (Value)
  • 3.5 Hit-to-Lead Optimization & Compound Screening Services (Value)
  • 3.6 Bioinformatics & Computational Biology Services (Value)
04Market Segmentation by Therapeutic Application
  • 4.1 Market by Therapeutic Application Overview
  • 4.2 Oncology & Immuno-Oncology Drug Discovery (Value)
  • 4.3 Infectious Disease & Antimicrobial Drug Discovery (Value)
  • 4.4 Central Nervous System & Neurological Disorders (Value)
  • 4.5 Cardiovascular & Metabolic Disease Drug Discovery (Value)
  • 4.6 Rare & Genetic Disease Target Discovery (Value)
05Market Segmentation by End User
  • 5.1 End-User Overview
  • 5.2 Domestic Indian Pharmaceutical Companies (Value)
  • 5.3 Multinational Pharmaceutical & Biotech Clients (Value)
  • 5.4 Academic & Government Research Institutions (Value)
  • 5.5 Indian Biotech Startups & Virtual Drug Discovery Companies (Value)
06India Regional & State-Level Market Forecast
  • 6.1 India Regional Revenue Share & Growth (2024 vs 2032)
  • 6.2 South India — Karnataka, Telangana & Tamil Nadu (Bengaluru-Hyderabad-Chennai Cluster)
  • 6.3 West India — Maharashtra (Pune-Mumbai Pharma & Biotech Hub)
  • 6.4 North India — Delhi NCR, Chandigarh & Uttar Pradesh (NOIDA Biotech Corridor)
  • 6.5 East India — West Bengal & Odisha (Emerging CRO & Academic Cluster)
  • 6.6 Central India — Madhya Pradesh & Chhattisgarh (Government-Backed Research Parks)
07Growth Drivers & Inhibitors
  • 7.1 GenomeIndia Initiative & National Genomics Grid Buildout Fueling Data Infrastructure
  • 7.2 Cost-Arbitrage Advantage in Multi-Omics Profiling Attracting Global CRO Mandates
  • 7.3 Domestic Indian Pharma Transition from Generic Manufacturing to Novel Target Discovery
  • 7.4 Market Restraints & Challenges
  • 7.5 Opportunities & White-Space Analysis
08Key Company Profiles
  • 8.1 Syngene International — Revenue, Strategy, Key Services
  • 8.2 Jubilant Biosys — Revenue, Strategy, Key Services
  • 8.3 Aurigene Oncology (Dr. Reddy's Subsidiary) — Revenue, Strategy, Key Services
  • 8.4 Lambda Therapeutic Research — Revenue, Strategy, Key Services
  • 8.5 Anthem Biosciences — Revenue, Strategy, Key Services
  • 8.6 Divi's Laboratories (Discovery Services Division) — Revenue, Strategy, Key Services
  • 8.7 Aragen Life Sciences (formerly GVK Biosciences) — Revenue, Strategy, Key Services
  • 8.8 Connexios Life Sciences — Revenue, Strategy, Key Services
  • 8.9 Eurofins Scientific India (Genomics Division) — Revenue, Strategy, Key Services
  • 8.10 Xcelris Labs — Revenue, Strategy, Key Services
09Competitive Landscape
  • 9.1 Market Concentration & Competitive Intensity Among Indian CROs
  • 9.2 Market Share Analysis (2024)
  • 9.3 Competitive Positioning Matrix — Service Breadth vs. Scientific Depth
  • 9.4 Recent Developments: M&A, Partnerships & Platform Launches (2023-2025)
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitute Products
  • 10.5 Competitive Rivalry Intensity
11PESTLE Analysis
  • 11.1 Political Factors — Government Policy, DBT & DST Funding Programs
  • 11.2 Economic Factors — Rupee Dynamics, R&D Investment Trends
  • 11.3 Social & Demographic Factors — Indian Patient Population Diversity & Disease Burden
  • 11.4 Technological Factors — NGS Cost Curves, AI-Driven Target Discovery Platforms
  • 11.5 Legal & Regulatory Factors — IP Protection, CDSCO Alignment & Data Privacy Norms
  • 11.6 Environmental Factors — Lab Waste Management & Sustainable Research Practices
12SWOT Analysis
  • 12.1 Market-Level Strengths — Scientific Talent Pool & Cost Competitiveness
  • 12.2 Market-Level Weaknesses — IP Perception Gap & Instrumentation Import Dependency
  • 12.3 Strategic Opportunities — Precision Medicine Pipeline Expansion & Biosimilar Discovery
  • 12.4 External Threats — Geopolitical Trade Disruption & Competing Asian CRO Markets
13Future Trends & Outlook
  • 13.1 Adoption of AI-Powered Target Deconvolution Platforms by Indian CROs
  • 13.2 Rise of India-Originated Biomarker Panels Derived from Indigenous Population Genomic Studies
  • 13.3 Integrated Multi-Omics CRO Service Models Replacing Siloed Genomics-Only Contracts
  • 13.4 Long-Term Market Outlook (2033-2035)
  • 13.5 Investment & M&A Activity Outlook

Frequently asked questions

What is the size of the India genomics, proteomics, and target-based drug discovery outsourcing market?
The India genomics, proteomics, and target-based drug discovery outsourcing market was valued at approximately USD 1.18 billion in 2024 (base year). The market is projected to reach approximately USD 3.05 billion by 2032, reflecting the compounding impact of domestic pharmaceutical company investment in novel drug discovery and sustained international CRO mandate flows into India.
What is the CAGR of the India genomics, proteomics, and target-based drug discovery outsourcing market?
The market is projected to grow at a compound annual growth rate (CAGR) of approximately 12.6% over the 2025–2032 forecast period, making it one of the higher-growth segments within India's broader contract research and life sciences services sector.
What is driving growth in the India genomics, proteomics, and target-based drug discovery outsourcing market?
Three principal drivers underpin growth: first, the Government of India's GenomeIndia initiative and related national genomics infrastructure programs are generating large-scale indigenous datasets that Indian CROs can monetize through discovery partnerships. Second, Indian CROs offer multi-omics profiling services at 40–60% lower cost than Western equivalents, sustaining strong international mandate flow. Third, domestic Indian pharmaceutical companies — historically generic-focused — are increasingly commissioning target-based discovery programs, expanding the internal buyer base and funding CRO capacity expansion across the Bengaluru-Hyderabad-Pune corridor.
Who are the leading companies in the India genomics, proteomics, and target-based drug discovery outsourcing market?
Leading companies include Syngene International (Bengaluru, a Biocon subsidiary and India's largest integrated CRO), Aragen Life Sciences (formerly GVK Biosciences, Hyderabad), Jubilant Biosys (Noida, computational and structural biology focus), Aurigene Oncology (a Dr. Reddy's subsidiary with deep oncology target expertise), and Anthem Biosciences (Bengaluru, integrated discovery and development services). These organizations collectively account for a substantial share of India's high-complexity outsourced discovery revenue.
Which region within India dominates the genomics, proteomics, and target-based drug discovery outsourcing market?
South India — specifically the Bengaluru-Hyderabad-Chennai cluster spanning Karnataka, Telangana, and Tamil Nadu — dominates the Indian market, accounting for an estimated 55–60% of total market revenue in 2024. This concentration reflects the presence of anchor CROs such as Syngene, Aragen, and Aurigene in these cities, supported by proximity to Indian Institutes of Science, CSIR laboratories, and international airport connectivity facilitating client interactions.
What segments are covered in this report?
The report covers the market across four primary segmentation dimensions: by service type (genomics sequencing, proteomics profiling, target identification and validation, hit-to-lead optimization, and bioinformatics services); by therapeutic application (oncology, infectious disease, CNS, cardiovascular/metabolic, and rare/genetic diseases); by end user (domestic Indian pharma companies, multinational pharma and biotech clients, academic and government institutions, and biotech startups); and by India region and state cluster.
What is the forecast period covered in this report?
The report covers a forecast period from 2025 to 2032, with 2024 serving as the base year. Historical market data and trend analysis are provided for the period 2019–2024 to contextualize the forecast within the market's post-pandemic growth trajectory and pre-GenomeIndia baseline.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from ‏1,495.00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.